Logo

MDXG

MiMedx Group, Inc.

MDXG

MiMedx Group, Inc. • NASDAQ
$6.88 ▲ 0.00% (+0.00)
Market Cap $1.02 B
52w High $10.14
52w Low $5.79
Dividend Yield 0%
P/E 25.48
Volume 226.77K
Outstanding Shares 148.10M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $113.725M ▲ $72.816M ▲ $16.748M ▲ 14.727% ▲ $0.11 ▲ $28.924M ▲
Q2-2025 $98.605M ▲ $67.554M ▲ $9.618M ▲ 9.754% ▲ $0.065 ▲ $15.514M ▲
Q1-2025 $88.205M ▼ $63.396M ▼ $7.023M ▼ 7.962% ▼ $0.05 ▼ $11.478M ▼
Q4-2024 $92.907M ▲ $64.944M ▲ $7.438M ▼ 8.006% ▼ $0.051 ▼ $14.138M ▲
Q3-2024 $84.057M $57.573M $8.095M 9.63% $0.055 $12.615M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $142.083M ▲ $318.988M ▲ $80.042M ▲ $238.946M ▲
Q2-2025 $118.869M ▲ $291.109M ▲ $74.485M ▲ $216.624M ▲
Q1-2025 $106.431M ▲ $270.42M ▲ $67.644M ▼ $202.776M ▲
Q4-2024 $104.416M ▲ $263.915M ▲ $70.808M ▲ $193.107M ▲
Q3-2024 $88.801M $243.891M $62.883M $181.008M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $16.748M ▲ $29.329M ▲ $-5.258M ▼ $-857K ▲ $23.214M ▲ $25.41M ▲
Q2-2025 $9.616M ▲ $14.419M ▲ $-887K ▼ $-1.094M ▲ $12.438M ▲ $14.419M ▲
Q1-2025 $7.023M ▼ $5.299M ▼ $-406K ▲ $-2.878M ▼ $2.015M ▼ $4.922M ▼
Q4-2024 $7.438M ▼ $18.782M ▼ $-2.767M ▼ $-400K ▼ $15.615M ▼ $18.782M ▲
Q3-2024 $7.878M $19.624M $113K $27K $19.764M $14.401M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Surgical
Surgical
 $30.00M ▲$30.00M ▲$30.00M ▲$40.00M ▲

Five-Year Company Overview

Income Statement

Income Statement MiMedx has shifted from a period of losses to a stretch of profitable growth. Sales have been climbing at a steady, healthy pace over the last several years, and the company has been able to keep a large share of those sales as gross profit, which points to good pricing power and a differentiated product set. Operating results moved from red ink to consistent operating profit, suggesting better cost discipline and scale benefits. One watchpoint: net profit dipped a bit most recently despite higher sales, which can indicate higher spending, pricing pressure, or one-time items. Overall, the story is one of a small but increasingly profitable business, with some normal volatility as it invests for growth.

Balance Sheet

Balance Sheet The balance sheet has improved meaningfully. The company moved from thin or even negative equity a few years ago to a more solid positive equity position, showing that past balance sheet stress has been worked through and retained earnings are building. Cash levels are healthy relative to the size of the business, while debt is modest and has been edging down, reducing financial risk. Total assets have been growing, but not in a way that suggests over-expansion or heavy leverage. In plain terms, MiMedx now looks financially sturdier and less fragile than it did earlier in the decade.

Cash Flow

Cash Flow Cash generation has turned into a clear strength. Operating cash flow shifted from negative or flat to consistently positive, and free cash flow has followed the same path, meaning the business is now funding itself and still producing excess cash. Capital spending is very light, which fits an asset-light, technology-focused model and helps convert earnings into cash. The main risk to watch is whether stronger cash flow is sustainable if the company continues to invest heavily in sales, clinical trials, and new product launches. For now, the trend is toward a healthier, more self-financing operation.

Competitive Edge

Competitive Edge MiMedx operates in a specialized corner of regenerative medicine, focused on placental tissue products, where it has carved out a defensible niche. Its proprietary processing method, large patent portfolio, and deep clinical data create meaningful barriers to entry and help differentiate products like EPIFIX and AMNIOFIX from rivals. The company also benefits from an established sales force and relationships with hospitals and payers, which are not easy for new entrants to replicate quickly. On the risk side, it still faces strong competition from larger wound-care and med‑tech players, exposure to shifting reimbursement policies, and regulatory scrutiny around tissue-based products. Its position is strong for its size, but not immune to competitive and policy changes.

Innovation and R&D

Innovation and R&D Innovation is at the core of MiMedx’s strategy. The company has built a broad patent estate around its PURION processing and placental tissue applications, and it backs this up with a sizable body of clinical studies, including randomized trials. Newer products like EPIEFFECT, AXIOFILL, AMNIOEFFECT, and EPIXPRESS show that management is actively extending the core technology into more wound types and surgical settings, not just relying on older products. The knee osteoarthritis program is a high-upside but higher-risk effort: earlier trial results were mixed, and success in later-stage studies is uncertain but could open a much larger market. Overall, R&D and clinical spending are strategic levers that support long-term growth but can pressure margins in the near term if payoffs are delayed.

Summary

MiMedx has transitioned from a troubled, loss-making period into a more stable, growing, and profitable business with improving cash flow and a stronger balance sheet. Its edge comes from a focused, placental-tissue technology platform backed by patents and clinical evidence, giving it a solid niche in advanced wound care and surgical applications. At the same time, it operates in a competitive and heavily regulated healthcare environment, with meaningful exposure to reimbursement decisions and clinical trial outcomes. The company’s future trajectory will likely hinge on continued adoption of its newer wound and surgical products and whether its larger, more ambitious programs—such as knee osteoarthritis—can successfully convert scientific promise into commercially viable therapies.

NEWS

November 13, 2025 · 8:00 AM UTC

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

Read more

November 3, 2025 · 9:15 AM UTC

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

Read more

October 29, 2025 · 4:01 PM UTC

MIMEDX Announces Record Revenue for Third Quarter 2025

Read more

October 15, 2025 · 8:00 AM UTC

MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29

Read more

October 6, 2025 · 9:28 AM UTC

MIMEDX Announces Launch of EPIXPRESS®

Read more